Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,305 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with multiple myeloma.
Gavriatopoulou M, Terpos E, Ntanasis-Stathopoulos I, Malandrakis P, Eleutherakis-Papaiakovou E, Papatheodorou A, Kanellias N, Migkou M, Fotiou D, Dialoupi I, Roussou M, Kokkali NA, Kastritis E, Dimopoulos MA. Gavriatopoulou M, et al. Among authors: dimopoulos ma. Blood Cancer J. 2020 Mar 2;10(3):25. doi: 10.1038/s41408-020-0297-2. Blood Cancer J. 2020. PMID: 32123158 Free PMC article. No abstract available.
Myeloma bone disease and proteasome inhibition therapies.
Terpos E, Sezer O, Croucher P, Dimopoulos MA. Terpos E, et al. Among authors: dimopoulos ma. Blood. 2007 Aug 15;110(4):1098-104. doi: 10.1182/blood-2007-03-067710. Epub 2007 May 9. Blood. 2007. PMID: 17494860 Free article. Review.
A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis.
Kastritis E, Terpos E, Roussou M, Gavriatopoulou M, Pamboukas C, Boletis I, Marinaki S, Apostolou T, Nikitas N, Gkortzolidis G, Michalis E, Delimpasi S, Dimopoulos MA. Kastritis E, et al. Among authors: dimopoulos ma. Blood. 2012 Jun 7;119(23):5384-90. doi: 10.1182/blood-2011-12-396903. Epub 2012 Apr 18. Blood. 2012. PMID: 22517904 Free article. Clinical Trial.
Optimal use of bisphosphonates in patients with multiple myeloma.
Terpos E, Roodman GD, Dimopoulos MA. Terpos E, et al. Among authors: dimopoulos ma. Blood. 2013 Apr 25;121(17):3325-8. doi: 10.1182/blood-2012-10-435750. Epub 2013 Feb 13. Blood. 2013. PMID: 23407550 Free article. Review. No abstract available.
Solitary bone plasmacytomas need to flow.
Dimopoulos MA, Terpos E. Dimopoulos MA, et al. Blood. 2014 Aug 21;124(8):1209-10. doi: 10.1182/blood-2014-06-579706. Blood. 2014. PMID: 25147376 Free PMC article.
Treatment options for relapsed and refractory multiple myeloma.
Nooka AK, Kastritis E, Dimopoulos MA, Lonial S. Nooka AK, et al. Among authors: dimopoulos ma. Blood. 2015 May 14;125(20):3085-99. doi: 10.1182/blood-2014-11-568923. Epub 2015 Apr 2. Blood. 2015. PMID: 25838342 Free article. Review.
Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenström macroglobulinemia: final analysis of a phase 2 study.
Kastritis E, Gavriatopoulou M, Kyrtsonis MC, Roussou M, Hadjiharissi E, Symeonidis A, Repoussis P, Michalis E, Delimpasi S, Tsatalas K, Tsirigotis P, Vassou A, Vervessou E, Katodritou E, Gika D, Terpos E, Dimopoulos MA. Kastritis E, et al. Among authors: dimopoulos ma. Blood. 2015 Sep 10;126(11):1392-4. doi: 10.1182/blood-2015-05-647420. Blood. 2015. PMID: 26359434 Free article. Clinical Trial. No abstract available.
1,305 results